Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy – 2 case studies

Abstract

This is a preliminary report of the first cases of successful simultaneous use of ulipristal acetate (UPA) and vitamin D3 in uterine fibroid (UF) oral treatment in humans. We present two cases of 37- and 49-year-old females with clinically symptomatic UFs and vitamin D deficiency. Both patients were treated with a standard 3 months of UPA scheme (5 mg daily) with the additional use of vitamin D3 (7000 IU daily orally). In the 37-year-old female all the symptoms (pain, pressure, frequent urination) decreased, total tumor volume after the treatment changed by 47.8%. In the 49-year-old female most symptoms perished, total tumor volume was reduced by 63.3%. UPA and vitamin D share synergistic anti-fibroid properties. Further studies are necessary to show the exact effect of UPA and vitamin D as co-drugs.

摘要：

这是首次成功地联合应用醋酸乌利司他(UPA)和维生素D3治疗人类子宫肌瘤(UF)的初步报告。报告中的两例患者分别是37岁和49岁女性, 具有子宫肌瘤的临床症状和维生素D缺乏症。两名患者均接受标准的UPA方案治疗3个月(每日5mg), 并额外用维生素D3(每日口服7000IU)。37岁女性患者所有症状(疼痛、压力、尿频)均有所减轻, 治疗后肌瘤缩小了47.8%。在49岁女性患者中, 大部分症状消失, 肌瘤缩小了63.3%。UPA和维生素D具有协同抗子宫肌瘤作用。进一步研究UPA和维生素D作为联合用药的确切效果是必要的。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Ulipristal acetate
• vitamin D
• uterine fibroid
• synergism
• pharmacology
• therapy

Acknowledgements

Both patients agreed to present their data. All the authors read and approved the final version of the manuscript.

Disclosure statement

Authors declare no conflict of interest.

Figure 1. Patient 1 – uterine fibroid before and after treatment.

Figure 2. Patient 2 – uterine fibroids before and after treatment.

Additional information

Funding

This study was funded by The Center of Postgraduate Medical Education.Grant number 501–1-21–27-17.